Augmented bioavailability and cysticidal activity of albendazole reformulated in soybean emulsion in mice infected with Echinococcusgranulosus or Echinococcusmultilocularis

Shuhua, Xiao; You, Jie; Wang, Mingjie; Pieying, Jiao; Fanghua, Gao; Chai, Jiake; Wei, Jiao; Hotez, Peter J.

doi:10.1016/s0001-706x(02)00027-x

Cited by 32 publications

(26 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In conclusion, a marked anthelmintic effect of ABZ was observed only upon 15 days of treatment twice a day. This effective treatment period was shorter than that reported by other authors in analogous murine models (Stettler et al 2004;Shuhua et al 2002;Rodrigues et al 1995).…”

Section: Discussionmentioning

confidence: 53%

“…9 Transmission electron microscopy (TEM) of hydatid cysts recovered from artificially infected mice and treated with albendazole (ABZ; regimen II). Just as the previous one, note the altered tissue with vacuoles (v), residual lamellar body (b) and lipid droplets (l; ×8,000) 1999), ABZ complexation with povidone (Evrard et al 2002) or an ABZ soybean oil emulsion (Shuhua et al 2002) have been shown to markedly enhance the ABZSO plasma levels in comparison with the conventional suspension. As similar C max values for ABZSO were observed after the administration of both ABZ formulations, the higher AUC value obtained after the ABZ solution was related to the longer ABZSO residence in the bloodstream (longer detection in plasma) observed in this experimental group.…”

Section: Discussionmentioning

confidence: 68%

See 1 more Smart Citation

Albendazole treatment in cystic echinococcosis: pharmacokinetics and clinical efficacy of two different aqueous formulations

et al. 2008

View full text Add to dashboard Cite

The pharmacokinetic (PK) behaviour and clinical efficacy of albendazole (ABZ) against hydatid cysts in mice were assessed after treatment with two different ABZ pharmaceutical formulations. BalbC mice received ABZ (0.5 mg/kg) prepared either as solution or suspension (50 microg/ml) for oral administration (PK study). Blood samples were collected up to 16 h post-treatment and processed to measure ABZ/metabolites concentrations in plasma. The clinical efficacy assessment was performed in BalbC mice infected 8 months earlier with Echinococcus granulosus protoscoleces. Infected animals were allocated into three experimental treatment groups: (a) untreated control, (b) ABZ-solution treated, (c) ABZ-suspension treated. Both treated groups received ABZ (0.5 mg/kg) administered under two different therapeutic schemes: dosing every 48 h over 30 days (regimen I) or treated every 12 h during 15 days (regimen II). Experimental mice were sacrificed 12 h after treatment, and cysts were recovered, weighed and processed for transmission electron microscopy. Enhanced ABZ sulphoxide (the main ABZ metabolite) concentration profiles were measured in animals treated with the ABZ solution. Any positive clinical response was obtained after treatment every 48 h (30 days therapy). However, consistent with the observed PK results, both ABZ formulations were clinically effective in infected mice treated with a 12-h dosing interval (15 days therapy).

show abstract

Section: Discussionmentioning

confidence: 53%

Section: Discussionmentioning

confidence: 68%

Albendazole treatment in cystic echinococcosis: pharmacokinetics and clinical efficacy of two different aqueous formulations

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Therapeutic failures attributed to medical management of CE with ABZ have been primarily linked to the poor drug absorption rate (<5%) resulting in low drug level in plasma and cysts (Shuhua et al, 2002). On the other hand, the poor water solubility of ABZ offers only few formulation possibilities, limiting the administration routes (Alanazi et al, 2007).…”

Section: Introductionmentioning

confidence: 99%

“…Regarding this, different efforts related to the formulation process have been made to enhance ABZ water solubility and dissolution rate such as soybean oil emulsion (Shuhua et al, 2002), liposomes (Dvorožňáková et al, 2004), cyclodextrins (Palomares-Alonso et al, 2010), and solid dispersions (Castro et al, 2012). In addition, several clinical studies have demonstrated that enhanced systemic availability of the parent drug/active metabolite obtained by increased drug absorption correlates with an improved antiparasitic effect (Shuhua et al, 2002;Dvorožňáková et al, 2004;Ceballos et al, 2008;Palomares-Alonso et al, 2010;Pensel et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

Cystic echinococcosis therapy: Albendazole-loaded lipid nanocapsules enhance the oral bioavailability and efficacy in experimentally infected mice

et al. 2015

View full text Add to dashboard Cite

“…At this time, albendazole is routinely used pre-and postoperatively in humans and as a treatment of choice for inoperative cystic echinococcosis (29,30). However, failures such as poor absorption in the intestinal tract, low levels of hepatic concentration, high cost, severe side effects, such as liver toxicity, and resistance have been reported for albendazole (30)(31)(32)(33)(34).…”

Section: Discussionmentioning

confidence: 99%

In Vivo Study of the Efficacy of the Aromatic Water of Zataria multiflora on Hydatid Cysts

Moazeni

Larki

Saharkhiz

et al. 2014

Antimicrob Agents Chemother

View full text Add to dashboard Cite

c Gas chromatography (GC) and gas chromatography-mass spectrometry (GC-MS) were employed to determine the chemical composition of the essential oil (EO) from aromatic water (AW) of Zataria multiflora. Thymol (66.9%), carvacrol (15.2%), and carvone (7.3%) were found to be the major EO constituents. Eighty laboratory BALB/c mice were infected intraperitoneally by injection of 1,500 viable protoscolices and were divided into prevention (40 mice) and therapeutic (40 mice) groups. To prove the preventive effect of the Z. multiflora AW on development of hydatid cysts, the 40 infected mice were allocated into three treatment groups, including the albendazole group (10 mice that received 150 mg/kg body weight/day for 10 days), the Z. multiflora AW group (15 mice that received 20 ml/liter in drinking water for 8 months), and a control group (15 mice that received no treatment). To estimate the therapeutic effect of the Z. multiflora AW on the hydatid cyst, after 8 months of infection, the 15 remaining mice were allocated into three experimental treatment groups of five animals each, including the albendazole group (300 mg/ kg/day for 20 days), Z. multiflora AW group (40 ml/liter in drinking water for 30 days), and control group (no treatment). All mice were then euthanized, and the sizes and weights of the cysts as well as their ultrastructural changes were investigated. The weights and sizes of the hydatid cysts significantly decreased upon treatment with the Z. multiflora AW in both the preventive and therapeutic groups (P < 0.05). The results of scanning electron microscopy also showed considerable damage in the germinal layer of the hydatid cysts recovered from the treated animals.

show abstract

Augmented bioavailability and cysticidal activity of albendazole reformulated in soybean emulsion in mice infected with Echinococcusgranulosus or Echinococcusmultilocularis

Cited by 32 publications

References 3 publications

Albendazole treatment in cystic echinococcosis: pharmacokinetics and clinical efficacy of two different aqueous formulations

Albendazole treatment in cystic echinococcosis: pharmacokinetics and clinical efficacy of two different aqueous formulations

Cystic echinococcosis therapy: Albendazole-loaded lipid nanocapsules enhance the oral bioavailability and efficacy in experimentally infected mice

In Vivo Study of the Efficacy of the Aromatic Water of Zataria multiflora on Hydatid Cysts

Contact Info

Product

Resources

About